Table 2.
Changes in clinical laboratory indicators at the end of 3 and 6 months in the traditional treatment group and sirolimus group.
| Traditional treatment group (n = 28) | Sirolimus group (n = 28) | |||||
|---|---|---|---|---|---|---|
| 0 month | 3 months | 6 months | 0 month | 3 months | 6 months | |
| Percentage of lymphocytes | 13.91 ± 3.37 | 21.46 ± 2.64* | 23.40 ± 4.46 | 13.97 ± 3.49 | 26.41 ± 3.58*# | 41.36 ± 6.27# |
| SLEDAI | 11.26 ± 3.49 | 9.46 ± 1.92* | 4.53 ± 2.32 | 11.33 ± 2.46 | 6.26 ± 2.25*# | 1.73 ± 1.48# |
| negative rate of anti-dsDNA | 0 (0%) | 4 (14.2%) | 9 (32.1%) | 0 (0%) | 10 (36%)# | 22 (78.6%)# |
| Positive rate of anti-dsDNA | 28 (100%) | 24 (85.8%) | 19 (67.9%) | 28 (100%) | 18 (64.3%)# | 6 (21.4%)# |
| Complement C3 | 0.62 ± 0.13 | 0.99 ± 0.15* | 1.23 ± 0.10 | 0.66 ± 0.13 | 1.02 ± 0.19* | 1.24 ± 0.22 |
| Complement C4 | 0.08 ± 0.03 | 0.18 ± 0.04* | 0.20 ± 0.05 | 0.10 ± 0.03 | 0.19 ± 0.05* | 0.21 ± 0.06 |
| Triglycerides | 1.93 ± 0.63 | 2.03 ± 0.56* | 2.94 ± 0.96 | 1.86 ± 0.66 | 2.41 ± 0.94* | 2.99 ± 1.01 |
| Total cholesterol | 4.08 ± 1.22 | 4.87 ± 1.79* | 4.99 ± 1.72 | 3.99 ± 1.03 | 4.52 ± 1.44* | 5.17 ± 1.89 |
| 24 h urinary protein ≥ 0.5 g/24 h | 20 | 0 | 0 | 19 | 0 | 0 |
| White blood cell count <4.0 × 109/L | 9 | 4 | 1 | 10 | 5 | 2 |
| Platelet count <100 × 109/L | 6 | 0 | 0 | 8 | 0 | 0 |
| Hemoglobin <100 g/L | 7 | 1 | 0 | 9 | 3 | 1 |
| IgG (g/L) quartile | 20 [17–28] | 14 [10–16] | 9.9 [8.55–10.85] | 18 [17–25] | 16 [14–19] | 14 [9.325–17.00] |
| Anti-nuclear antibody | 28 | 26 | 25 | 28 | 25 | 25 |
Compared with SLE before treatment, *P < 0.05; Compared with the traditional treatment group, #P < 0.05.